Validity and reliability of sprint force-velocity profiling in elite football: Comparison of MySprint, GPS, and radar devices
PLOS One · 2025
DOI: 10.1371/journal.pone.0325611 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Robert A Stockdale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lancaster Medical School, Health Innovation One, Sir John Fisher Drive, Lancaster University, Lancaster, United Kingdom. Hauptthemen laut MEDLINE: Geographic Information Systems, Radar, Running, Athletic Performance. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The aims were to examine the validity and within-session inter-trial, intra- and interrater reliability of sprint force-velocity profiling (FVP) techniques in elite football. Twelve elite youth football players from an English Premier League academy participated in this study. A 30-m maximal effort linear sprint testing protocol was conducted, simultaneously measured using the MySprint app, GPS units, and radar device to derive theoretical maximal horizontal force (F 0 ), theoretical maximal running velocity (V 0 ), and the overall orientation of the profile (FV slope ). There were significant differences in F 0 , V 0 , and FV slope (p < 0.05) between the MySprint app and radar device, with large effect sizes (ε 2 = 0.683, 0.513, and 0.482), but not in F 0 or V 0 (p > 0.05), between the GPS and radar devices. There were no significant differences in F 0 or V 0 (p > 0.05) between each players’ sprint repeats for all equipment types, with these effect sizes (r rb ): MySprint (0.047, 0.523), GPS (0.236, −0.163), radar (0.785, −0.777). RMSE and CV values for F 0 and V 0 were 0.72–1.20 N/Kg and 3.76–9.59%, 0.21–0.40 m/s and 1.48–2.64%, respectively, with improved reliability and agreement in V 0 vs. F 0 . There was no significant difference in F 0 or V 0 (p > 0.05), with medium-to-large effect sizes (r rb = −0.242 and −0.636) when the MySprint analysis was repeated by the same rater. RMSE and CV values for F 0 and V 0 were 0.19 N/Kg and 2.9%, 0.07 m/s and 0.54%. There was no significant difference in F 0 or V 0 (p > 0.05) between the two raters’ MySprint analysis, and ICC demonstrated excellent agreement (F 0 = 0.986, CI = 0.950–0.996, and V 0 = 0.988, CI = 0.957–0.997). This study reports high intra- and inter-rater reliability when using the MySprint app to derive FVP’s from 30-m maximal sprint testing whilst indicating GPS as the most valid and reliable force-velocity profiling technique against the reference radar device.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Lancaster Medical School, Health Innovation One, Sir John Fisher Drive, Lancaster University, Lancaster, United Kingdom.
- Department of Sport and Exercise Sciences, Manchester Institute of Sport, Manchester Metropolitan University, Manchester, United Kingdom.
- Department of Computing and Mathematics, Institute of Technology, Dundalk, Ireland.
ORCID-Profile: Robert A Stockdale, Thomas Dos'Santos, Philip Nagy, Christopher J Gaffney
Zitieren
APA
Stockdale, R. A., Dos'Santos, T., McDaid, K., Nagy, P., Gaffney, C. J., & Barry, T. J. (2025). Validity and reliability of sprint force-velocity profiling in elite football: Comparison of MySprint, GPS, and radar devices. PLOS One. https://doi.org/10.1371/journal.pone.0325611
Vancouver
Stockdale RA, Dos'Santos T, McDaid K, Nagy P, Gaffney CJ, Barry TJ. Validity and reliability of sprint force-velocity profiling in elite football: Comparison of MySprint, GPS, and radar devices. PLOS One. 2025. doi:10.1371/journal.pone.0325611
BibTeX
@article{Stockdale2025,
author = {Stockdale, Robert A and Dos'Santos, Thomas and McDaid, Kevin and Nagy, Philip and Gaffney, Christopher J and Barry, Timothy J},
title = {Validity and reliability of sprint force-velocity profiling in elite football: Comparison of MySprint, GPS, and radar devices},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0325611}
}
EUVIMED